Study evaluating the efficacy and safety of regorafenib as maintenance therapy after first-line treatment in patients with bone sarcomas.

Phase 1

• Conditions: Patients with bone sarcomas other than chordoma, who have no residual disease after their standard treatment sequence.; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2024-514637-37-00
• Lead Sponsor: Centre Leon Berard

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-15
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

I1. Age = 12 years at the day of consenting to the study;, I10. INR/PTT =1.5 x ULN; Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care;, I11. Women of childbearing potential and male patients must agree to use adequate contraception (Appendix 4) for the duration of treatment and for 7 months (210 days) in WOCBP or 4 months (120 days) in men sexually active with WOCBP after the last dose of regorafenib;, I12. Women of childbearing potential must have a negative serum ß-HCG pregnancy test within 7 days prior randomization and/or urine pregnancy test within 48 hours before the first administration of the study treatment;, I13. Patients, and their parents when applicable, must sign and date an informed consent document indicating that they have been informed of all the pertinent aspects of the trial prior to enrolment;, I14. Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures;, I15. Patients covered by a medical insurance., I16. Body Surface Area (BSA) = 1.30m² at the time of consenting to the study., I2. Patients must have histologically confirmed diagnosis of primary bone sarcoma including but not limited to: Osteosarcomas, Ewing sarcomas, Chondrosarcomas, Undifferentiated Pleomorphic Sarcomas (UPS), Leiomyosarcomas (LMS) and Angiosarcomas;, I3. Prior treatment for localized or metastatic disease for bone sarcoma must have been completed, consisting of a standard multimodal treatment based on the histological subtype: For OS, (excepted head and neck localisations), neoadjuvant and/or adjuvant chemotherapy should include methotrexate-based regimen for patients < 18 years old; patients = 18 years old may have received either methotrexate-based regimen or anthracycline and cisplatin-based regimen For head and neck OS, neoadjuvant and/or adjuvant chemotherapy should include adriamycin, cisplatin or ifosfamide-based regimen. For non-OS, neoadjuvant and/or adjuvant chemotherapy should include adriamycin and/or cisplatin-based regimen., I4.Retour à un grade 0 ou 1 de la classification NCI-CTCAE v5 ou retour à l’état initial avant le dernier traitement ou la dernière procédure (à l’exception de l’alopécie, l’anémie et l’hypothyroïdie), I5. Interval between the last chemotherapy administration and the date of randomisation: at least 4 weeks but no longer than 2 months;, I6. Confirmed complete remission or no evidence of disease (for metastatic disease); Patients with pulmonary micro nodules can be included provided they do not meet the following criteria: • At least one lung nodule of 10mm or more• And/or at least two nodules well limited between 6-9mm • And/or at least 5 nodules well limited of 5mm or less All the other situations will be considered as doubtful lesions except in case of metastatic disease confirmed during the lung surgery of the residual lung lesions after pre-operative chemotherapy. If no other metastatic localisation is detected at the initial staging, the patient will be considered as localised disease and eligible for randomisation., I7. Life expectancy of greater than 12 months;, I8. Karnofsky Performance status =70 (patients youn

Exclusion Criteria

E1. Prior treatment with any VEGFR inhibitor (thus, any prior exposure to sunitinib, sorafenib, pazopanib, bevacizumab, or other VEGFR inhibitor);, E10. Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy; Nota Bene: Subjects with a history of hepatitis B or C who have normal alanine aminotransferase (ALT) and are hepatitis B surface antigen negative and/or have undetectable HCV RNA are eligible;, E11. Dehydration according to NCI-CTC v5 Grade >1;, E12. Difficulties to swallow oral medication and/or any mal-absorption condition and/or any Gastrointestinal (GI) disease that may significantly alter the absorption of regorafenib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small bowel resection);, E13. Patients with seizure disorder requiring medication;, E14. Concurrent enrolment in another clinical trial in which investigational therapies are administered;, E15. Known hypersensitivity to the active substance or to any of the excipients;, E16. Pregnant women, women who are likely to become pregnant or are breast-feeding, E17. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;, E18. Patients with history of non-compliance to medical regimens or unwilling or unable to comply with the protocol;, E19. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent;, E2. All soft tissue sarcomas (including but not limited to soft tissue osteosarcomas and Ewing soft tissue sarcomas) and chordomas;, E20. Non-healing wound, non-healing ulcer, or non-healing bone fracture;, E21. Patients with evidence or history of any bleeding diathesis, irrespective of severity;, E22. Any haemorrhage or bleeding event = CTCAE v5 Grade 3 within 4 weeks prior to the first study drug administration;, E23. Clinically significant unrelated systemic illness (e.g., serious infection or significant cardiac, pulmonary, hepatic, or other organ dysfunction) that would compromise the patient's ability to tolerate study treatment or would likely interfere with study procedures or results;, E24. Patients using prohibited concomitant and/or concurrent medications (see section Prohibited concomitant/concurrent treatments);, E25. Patients under tutorship or curatorship., E3. Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix) within 3 years prior to randomization;, E4. Cardiovascular dysfunction: • Left ventricular ejection fraction (LVEF) < 50%, • Congestive heart failure = New York Heart Association (NYHA) class 2, • Myocardial infarction < 6 months prior to first study drug administration, • Cardiac arrhythmias requiring therapy (beta blockers or digoxin are permitted), • Unstable (angina symptoms at rest) or new-onset angina within the last 3 months prior to first study drug administration;, E5. Uncontrolled hypertension (systolic blood pressure > 150mmHg or diastolic pressure > 90 mmHg despite optimal treatment);, E6. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the last 6 months before the first study drug administration;, E7.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified